There were differences in multiple pathways between patients in the KRAS gene mutation group and patients in the nonmutation group, including immunodeficiency, natural killer cell-mediated cytotoxicity, JAK stat signaling pathway, etc. (Figure 7c). The gene discussed is KRAS; the disease is Immunodeficiency.